It has been previously shown that different antimicrobial susceptibility testing (AST) methodologies can influence susceptibility results for tigecycline (Hope et al., 2010; Cohen Stuart et al., 2010; Marchaim et al., 2014; Torrico et al., 2010) . Even within a single AST method, several testing conditions including medium age and ion content may cause discrepant results (Bradford et al., 2005; FernandezMazarrasa et al., 2009) . For tigecycline, Leal Castro et al. (2010) and Lat et al. (2011) provided early data demonstrating overestimation of MICs and resistance rates by Vitek 2 system. Our study, therefore, aimed to systematically determine the error rates of tigecycline AST for Enterobacteriaceae by Vitek 2 (focusing on false non-susceptible results) as well as other automated systems in comparison to a reference method. Additionally, we compared several other AST methods and testing conditions.
Enterobacteriaceae isolates tested as nonsusceptible to tigecycline [intermediate or resistant according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) (The European Committee on Antimicrobial Susceptibility Testing, 2012a), i.e. isolates with MIC !2 mg l À1 by Vitek 2 (bioM erieux) during the routine microbiological diagnostics at four university hospitals in Germany were prospectively collected (one isolate per patient) and sent to a coordinating centre (University Hospital Münster). Enterobacterial genera intrinsically resistant against tigecycline were excluded. MICs of 296 isolates non-susceptible to tigecycline according to the initial Vitek 2 routine testing at study centres were determined at the coordinating centre in triplicate by Vitek 2 for confirmation of Vitek 2 non-susceptibility. Isolates confirmed as non-susceptible by Vitek 2 (median MIC value) were subjected to a comparative AST by broth microdilution (BMD), automated AST systems Vitek 2, BD Phoenix (Becton Dickinson), MicroScan WalkAway 96 plus (Siemens Healthcare Diagnostics), Etest (bioM erieux) and disk diffusion.
Isolates were subcultured on the day before testing and incubated about 18 h before testing. All AST methods were performed on the same day from the same plate. BMD was performed according to the ISO 20776-1 guideline (ISO, 2006) using Micronaut-S 96-well microtiter plates (Merlin) containing tigecycline in twofold concentrations (0.016-16 mg l À1 ). After a preliminary experiment with 24 isolates showed no difference in MIC 50 and MIC 90 as well as in the rates of very major errors (VME) and major errors (ME) between freshly ( 12 h) prepared cation-adjusted Mueller-Hinton broth (CA-MHB; Merck) and commercially prepared BBLÔ cationadjusted Mueller-Hinton II broth (Becton Dickinson) available in tubes (see Tables  S1 and S2 , available in the online Supplementary Material), the latter was used throughout the study.
Vitek 2 testing was performed using the AST-N214 card according to the manufacturer's instructions. AST-N214 cards contained tigecycline at concentrations of 0.75, 2 and 4 mg l À1 and allowed a range of possible tigecycline MIC results of 0.5 to !8 mg l À1 owing to the proprietary kinetic growth algorithms (Ullery, 2006 By repeated Vitek 2 testing in triplicate, 81.4 % (241/296) of isolates initially categorized in routine diagnostics as tigecycline non-susceptible by Vitek 2 were confirmed to be non-susceptible. Of those confirmed non-susceptible isolates by Vitek 2 testing, 40.2 % were, in fact, susceptible according to the BMD reference method, applying the EUCAST breakpoints (Table 1) . Of the isolates, which were determined as non-susceptible by Vitek 2 testing according to the FDA breakpoints, 53.3 % were susceptible using BMD and applying the FDA breakpoints (Table S3) ; 58.1 % of the isolates had Vitek 2 MIC one double dilution step higher than a correspondent MIC from BMD (Table S4 ).
The amount of MEs and mEs was considerably lower with the two other automated systems BD Phoenix and MicroScan WalkAway (Tables 1 and S3 ). However, MicroScan WalkAway, as well as disk diffusion method, accounted each for one VME when evaluated according to the EUCAST (Table 1) (Table S5) .
Comparison between gradient diffusion tests from three different manufacturers performed on prepared plates of BBLÔ Mueller-Hinton II agar (Becton Dickinson) showed that MTS (Liofilchem) had the highest CA with BMD, followed by M. I. C. E. (Oxoid). Etest had the lowest CA and EA as well as highest ME and mE rates (Tables S6 and S7 ).
Comparison of Etest (bioM erieux) results performed on Mueller-Hinton agar from different manufacturers (Tables S6 and S7) showed the highest CA and EA and only mEs when tested on Bio-Rad agar. However, even with this medium, MICs were considerably overestimated compared to BMD. Etest on BD, bioM erieux and Oxoid media provided lower CA and EA and a considerable number of MEs and mEs. Notably, Merck medium had very poor performance by generating high MICs and very low CA and EA. All isolates were categorized as resistant on this medium. A much higher concentration of manganese in MuellerHinton agar from Merck has been reported to be responsible for higher tigecycline MICs produced by Etest with this medium (Fernandez-Mazarrasa et al., 2009) .
Disk diffusion testing on Mueller-Hinton agar from BD performed for all 241 isolates showed low CA with a trend to false non-susceptible categorization (Tables 1 and S3 ). When the results of the disk diffusion method for tigecycline were compared on Mueller-Hinton agar from different manufacturers (Table S8) , media from bioM erieux and Bio-Rad had higher CA, although each accounted one VME. Again, Merck agar showed considerable overestimation of resistance and, thus, poor performance. Disk diffusion seems to be of limited value for tigecycline susceptibility testing. Poor correlation of results from disk diffusion and dilution methods for tigecycline has also been reported from other studies (Hope et al., 2010) .
Additional testing of 70 isolates initially determined as susceptible by Vitek 2 with BMD and other methods has confirmed that susceptible Vitek 2 results for tigecycline can be trusted (Tables S9 and  S10 ).
Our study has demonstrated a high rate of false non-susceptible Vitek 2 tigecycline categorization for Enterobacteriaceae, which is in line with other recent reports (Huang et al., 2012; Zarkotou et al., 2012; Marchaim et al., 2014) . Because of the false results, patients infected with multidrug-resistant Enterobacteriaceae might be deprived of one of few remaining therapeutic options. Clinical laboratories should be aware of this failure, and isolates reported as non-susceptible by Vitek 2 should be re-tested by other method in particular when tigecycline represents a treatment option. Verification of such Vitek 2 results is recommended with BMD. The use of freshly ( 12 h) prepared broth is required for tigecycline BMD (ISO, 2006) , which is hardly possible to implement for routine laboratories. Our findings demonstrate that commercially available CA-MHB, supplied in tubes, can also be reliably used. This does not apply to the stored lots of CA-MHB prepared in the laboratory because they produce elevated MICs (Bradford et al., 2005) . Nevertheless, BMD itself is time consuming and might be difficult to perform in clinical laboratories. Unfortunately, Etest and disk diffusion methods both perform poorly for tigecycline susceptibility testing. If it is not possible to verify Vitek 2 nonsusceptible results by BMD, other automated AST devices, as well as MIC Test Strips (Liofilchem), may provide valuable information.
